Pandox AB (publ) (LON:0R8U)
London · Delayed Price · Currency is GBP · Price in SEK | Market Cap | 2.71B +8.3% |
| Revenue (ttm) | 607.64M +6.8% |
| Net Income | 291.73M +170.6% |
| EPS | 1.50 +163.5% |
| Shares Out | n/a |
| PE Ratio | 9.28 |
| Forward PE | 15.36 |
| Dividend | 0.36 (0.20%) |
| Ex-Dividend Date | Apr 16, 2026 |
| Volume | 13,197 |
| Average Volume | 19,196 |
| Open | 175.30 |
| Previous Close | 178.20 |
| Day's Range | 175.00 - 176.90 |
| 52-Week Range | 153.33 - 204.00 |
| Beta | 1.23 |
| RSI | 42.85 |
| Earnings Date | Apr 29, 2026 |
About Pandox AB
Pandox AB (publ) owns, develops, and leases hotel properties to skilled hotel operators under long-term, turnover based leases with minimum guaranteed levels. Since their inception in 1995, they have grown into one of the largest hotel property owners in Europe. Their portfolio consists of 193 hotel properties with approximately 43,000 rooms across 11 countries in Northern Europe. The portfolio market value is approximately SEK 90bn. The headquarters is in Stockholm, and we are listed on Nasdaq Stockholm. Pandox AB (publ) was established on Jan... [Read more]
Financial Performance
In 2025, Pandox AB's revenue was 7.47 billion, an increase of 4.67% compared to the previous year's 7.14 billion. Earnings were 3.14 billion, an increase of 85.85%.
Financial numbers in SEK Financial StatementsNews
Pandox AB Transcript: CMD 2025
A diversified European hotel portfolio is driving growth through active ownership, high-yielding investments, and sustainability initiatives. Recent acquisitions and disciplined capital allocation support robust cash flow and value creation, with a strong outlook for returns in a resilient market.
Pandox AB Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue and net operating income growth, led by the Dalata acquisition and robust Nordic performance, despite negative currency effects. The outlook remains positive with resilient intra-European travel, though geopolitical risks persist.
Pandox AB Earnings Call Transcript: Q4 2025
Q4 2025 saw strong like-for-like growth, boosted by the Dalata acquisition, which increased revenues, NOI, and international exposure. Financial metrics improved, with a 23% rise in cash earnings and a 7.7% EPRA NRV increase. 2026 outlook is positive, especially for the Nordics and Germany.
Pandox AB Earnings Call Transcript: Q3 2025
Q3 2025 saw revenue and NOI growth driven by acquisitions and strong Nordic demand, with the Dalata acquisition set to boost results from Q4 and 2026. Loan-to-value remains healthy, and the portfolio is well-diversified, while currency headwinds and one-off transaction costs are noted.
Pandox AB Earnings Call Transcript: Q2 2025
Q2 2025 delivered stable growth with revenue and net operating income up, supported by acquisitions. Guidance for 2025 remains stable, with positive outlook for H2 due to easier comps and ongoing investments. Financial position is strong, with ample capacity for further acquisitions.
Pandox AB Earnings Call Transcript: Q1 2025
Q1 2025 saw stable growth with revenues up 1% and net operating income up 5% year-over-year, driven by acquisitions and strong lease performance. Guidance for 2025 RevPAR growth remains at 0–4%, with a stable booking outlook and continued focus on value-creating acquisitions.
Pandox AB Earnings Call Transcript: Q4 2024
2024 delivered strong revenue and earnings growth, driven by strategic acquisitions and investments, with a solid outlook for 2025. The portfolio expanded, leverage remained stable, and the dividend is set to increase. European hotel market conditions remain favorable for continued growth.
Pandox AB Transcript: Hotel Market Day 2024
Growth is driven by strategic acquisitions, renovations, and a focus on high-yield hotel assets, with strong financials and resilience supported by intra-European travel. Macro trends highlight demographic shifts, technology adoption, and sustainability as key factors shaping the future of the hospitality sector.
Pandox AB Earnings Call Transcript: Q3 2024
Q3 saw 5% revenue and 3% net operating income growth year-over-year, with strong performance in both business segments and new acquisitions in London and Edinburgh at attractive yields. RevPAR growth is expected to continue into Q4 and 2025, though geopolitical risks remain a key uncertainty.
Pandox AB Earnings Call Transcript: Q2 2024
Q2 2024 delivered strong revenue and NOI growth of 6% year-over-year, with cash earnings up 10% and a robust pipeline set to add SEK 300 million in NOI by 2026. The company maintains a solid financial position, low refinancing risk, and expects continued hotel market growth, supported by limited new supply and strong event-driven demand.